Top M3541 Secrets
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review to evaluate various intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Main demo goals were to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositis sufferer